Phase
Condition
Depression (Treatment-resistant)
Depression (Major/severe)
Depression
Treatment
Lumateperone
Placebo
Clinical Study ID
Ages 10-17 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Able to provide consent as follows:
The Legally Authorized Representative (LAR) must provide written, informedconsent.
The patient must provide written assent;
Male or female patients 10 to 17 years of age, inclusive;
Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition TextRevision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with acurrent MDE without psychosis as confirmed by Kiddie Schedule for AffectiveDisorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL);
Subject has a lifetime history of at least one manic or hypomanic episode.
Subject's current major depressive episode is ≥ 4 weeks and less than 12 months induration;
CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening andBaseline;
Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 [elevated mood] score ≤
- at Screening and Baseline.
Exclusion
Exclusion Criteria:
- Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder.Exception includes:
- Attention deficit hyperactivity disorder (ADHD). If a subject is takingmedications for ADHD, they must have been on a stable treatment regimen ofthese medication(s) for 30 days prior to screening and the treatment regimen isexpected to remain stable throughout the study.
Intellectual disability based on Investigator opinion and DSM-5 criteria
Patient has been hospitalized for a bipolar manic episode within the 30 days priorto randomization;
Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score betweenScreening and Baseline visits, or the CDRS-R is below 45 at Baseline;
In the opinion of the Investigator, the patient has a significant risk for suicidalbehavior during his/her participation in the study or
At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 ofthe Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior toScreening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit;
At Screening, the patient has had 1 or more suicidal attempts within the 2years prior to Screening; or
At Screening or Baseline, scores > 3 on Item 13 (suicidal ideation) on theCDRS-R; or
The patient is considered to be an imminent danger to him/herself or others.
Study Design
Study Description
Connect with a study center
Clinical Site
Anaheim, California 92805
United StatesSite Not Available
Clinical Site
Sacramento, California 95817
United StatesSite Not Available
Clinical Site
San Diego, California 92103
United StatesSite Not Available
Clinical Site
Colorado Springs, Colorado 80910
United StatesSite Not Available
Clinical Site
Gainesville, Florida 32607
United StatesSite Not Available
Clinical Site
Hialeah, Florida 33012
United StatesSite Not Available
Clinical Site
Miami Lakes, Florida 33016
United StatesSite Not Available
Clinical Site
Miami Springs, Florida 33166
United StatesActive - Recruiting
Clinical Site
Orlando, Florida 32803
United StatesActive - Recruiting
Clinical Site
Atlanta, Georgia 30318
United StatesSite Not Available
Clinical Site
Decatur, Georgia 30030
United StatesActive - Recruiting
Clinical Site
Lawrenceville, Georgia 30046
United StatesActive - Recruiting
Clinical Site
Savannah, Georgia 31405
United StatesSite Not Available
Clinical Site
Chicago, Illinois 60611
United StatesSite Not Available
Clinical Site
Indianapolis, Indiana 46202
United StatesSite Not Available
Clinical Site
Baltimore, Maryland 21229
United StatesSite Not Available
Clinical Site
Saint Charles, Missouri 63304
United StatesSite Not Available
Clinical Site
Lincoln, Nebraska 68526
United StatesSite Not Available
Clinical Site
Kinston, North Carolina 28504
United StatesSite Not Available
Clinical Site
Avon Lake, Ohio 44012
United StatesSite Not Available
Clinical Site
Cincinnati, Ohio 45219
United StatesSite Not Available
Clinical Site
Garfield, Ohio 44125
United StatesSite Not Available
Clinical Site
Oklahoma City, Oklahoma 73116
United StatesSite Not Available
Clinical Site
Austin, Texas 78759
United StatesSite Not Available
Clinical Site
Frisco, Texas 75034
United StatesSite Not Available
Clinical Site
Houston, Texas 77090
United StatesSite Not Available
Clinical Site
Bellevue, Washington 98007
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.